Patents Assigned to Dana-Faber Cancer Institute, Inc.
-
Patent number: 10738310Abstract: This present invention compositions and methods of treating cancer and methods of accessing/monitoring the responsiveness of a cancer cell to a therapeutic compound.Type: GrantFiled: November 23, 2015Date of Patent: August 11, 2020Assignee: Dana-Faber Cancer Institute, Inc.Inventors: Alan D'Andrea, David T. Weaver, Markus Grompe, Richard Kennedy
-
Publication number: 20190314374Abstract: The present invention relates to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to the use of novel classes of compounds, i.e. inhibitors of RSK (p90S6K); inhibitors of p70S6K; and inhibitors of rps6, to treat ribosomal disorders and ribosomopathies. In some embodiments, the invention relates to the use of specific Chk2 inhibitors and to the use of specific phenothiazine derivatives to treat ribosomal disorders and ribosomopathies, e.g. DBA.Type: ApplicationFiled: July 13, 2017Publication date: October 17, 2019Applicants: The Children's Medical Center Corporation, Dana-Faber Cancer Institute, Inc.Inventors: James BRADNER, Jun QI, Dennis BUCKLEY, Leonard I. ZON, Elizabeth MACARI
-
Patent number: 10279021Abstract: The present invention provides compositions and methods for treating cancer in a subject by eliciting an immune response against a MIC polypeptide.Type: GrantFiled: March 16, 2015Date of Patent: May 7, 2019Assignee: Dana-Faber Cancer Institute, Inc.Inventors: Glenn Dranoff, Kai W Wucherpfennig, Christopher Harvey, F. Stephen Hodi
-
Systems, apparatus, and methods related to magnetically-controlled three-dimensional tissue cultures
Patent number: 10221381Abstract: Systems, devices, and methods for generating, culturing, and using magnetically-controlled three-dimensional (3D) tissues are described. A magnetically-enabled transwell system for immobilizing and supplying perfusion to a 3D mini-tissue includes a cell culture vessel with at least a first chamber and a second chamber, the mini-tissue being disposed in the first chamber, and a perfusion mechanism defining an elongate perfusion channel with a proximal end in the first chamber and a distal end in fluid communication with the second chamber, with a magnetic element configured to immobilize a magnetically-controlled 3D mini-tissue such that the proximal end is in fluid communication with basolateral space of the immobilized mini-tissue.Type: GrantFiled: June 30, 2015Date of Patent: March 5, 2019Assignee: Dana-Faber Cancer Institute, Inc.Inventors: Eugen Dhimolea, Constantine Mitsiades -
Publication number: 20180209985Abstract: In some embodiments, a mass spectrometry tag may comprise a linker region, a mass balance region, and a reporter region. The mass spectrometry tag may be configured to fragment in a mass spectrometer via an energy dependent process to produce multiple reporter molecules. For example, the reporter region of the tag may be configured to produce at least two reporter molecules via fragmentation. In some embodiments, one or more regions of the tag may comprise at least one heavy isotope. In some such embodiments, the ability to fragment into multiple reporter molecules as well as the placement and/or number of heavy isotope(s) allows the mass spectrometry tag to be distinguished from other similar mass spectrometry tags. In some such embodiments, the ability to distinguish between tags having the same or substantially similar total mass to charge ratio and reporter region mass may allow the system to have a greater multiplexing capacity than conventional systems.Type: ApplicationFiled: June 3, 2016Publication date: July 26, 2018Applicants: President and Fellows of Harvard College, Dana-Faber Cancer Institute, Inc.Inventors: Craig Braun, Wilhelm Haas, Steven P. Gygi, Gregory H. Bird, Loren D. Walensky, Martin Helmut Wuhr, Brian K. Erickson
-
METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF METABOLIC DISORDERS USING SLIT2
Publication number: 20180193416Abstract: The present invention relates to methods for identifying, assessing, preventing, and treating metabolic disorders and modulating metabolic processes using Slit2.Type: ApplicationFiled: July 15, 2016Publication date: July 12, 2018Applicant: Dana-Faber Cancer Institute, Inc.Inventors: Bruce M. Spiegelman, Katrin J. Svensson -
Patent number: 8715686Abstract: Isolated immunogens including a HIV-1 gp120 polypeptide or immunogenic fragment thereof stabilized in a CD4 bound confirmation by crosslinked cysteines, and methods of their use are disclosed. The immunogens are useful, for example, for generating an immune response to HIV-1 gp120 in a subject.Type: GrantFiled: August 14, 2012Date of Patent: May 6, 2014Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Dana-Faber Cancer Institute, Inc.Inventors: Peter Kwong, John Mascola, Gary Nabel, Richard Wyatt, Barna Dey, Ling Xu, Tongqing Zhou, Joseph Sodroski, Wen Yuan, Shi-Hua Xiang
-
Publication number: 20140106344Abstract: The invention provides methods of treating a meiotic kinase-associated disease, preferably the meiotic kinase HSET, by administering an inhibitor of the meiotic kinase. Preferably, the disease is associated with the presence of supernumerary centrosomes, such as cancer. Methods of inhibiting the growth of a tumor cell by contacting the cell with an inhibitor of a meiotic kinase, preferably HSET, are also provided. Screening methods for identifying inhibitors of the meiotic kinase HSET are also provided. Methods of selecting subjects for treatment with an inhibitor of a meiotic kinase, such as HSET, are also provided.Type: ApplicationFiled: December 11, 2013Publication date: April 17, 2014Applicant: Dana-Faber Cancer Institute, Inc.Inventor: David Pellman
-
Patent number: 7776541Abstract: The invention features methods of diagnosing high grade ductal carcinoma in situ (DCIS) These methods involve measuring: (1) the level of HID-5 in a body fluid (e.g., blood or urine) of a subject suspected of having, or at risk of having, high grade DCIS; or (2) the level of HID-5 gene expression in breast tissue from a subject suspected of having, or at risk of having, high grade DCIS. The invention also embodies a method of inhibiting expression of HID-5 protein in DCIS cells and methods of treating a subject suspected of having, or at risk of having, high grade DCIS.Type: GrantFiled: December 8, 2008Date of Patent: August 17, 2010Assignee: Dana-Faber Cancer Institute, Inc.Inventors: Kornelia Polyak, Charlotta Enerback
-
Patent number: 7381703Abstract: Aplidine and aplidine analogues are used in the manufacture of a medicament for treating multiple myeloma.Type: GrantFiled: March 12, 2004Date of Patent: June 3, 2008Assignees: Dana-Faber Cancer Institute, Inc., Pharma Mar, S.A.Inventors: Joseph R. Bertino, Daniel Medina, Glynn Thomas Faircloth, Constantine S. Mitsiades, Kenneth Anderson, Nicholas Mitsiades
-
Patent number: 7153934Abstract: Structural forms of T cell costimulatory polypeptides are described. These forms comprise an alternative structural domain (i.e., a structural domain having an amino acid sequence which differs from a known amino acid sequence) or have a structural domain deleted or added. The structural forms correspond to naturally-occurring alternatively spliced forms of T cell costimulatory polypeptides or variants thereof which can be produced by standard recombinant DNA techniques. In one embodiment, the T cell costimulatory polypeptide of the invention contains an alternative cytoplasmic domain. In another embodiment, the T cell costimulatory polypeptide of the invention contains an alternative signal peptide domain or has an immunoglobulin variable region-like domain deleted.Type: GrantFiled: September 24, 2001Date of Patent: December 26, 2006Assignees: Dana-Faber Cancer Institute, Inc., Brigham and Women's HospitalInventors: Arlene H. Sharpe, Francescopaolo Borriello, Gordon J. Freeman, Lee M. Nadler
-
Patent number: 7038013Abstract: The invention provides isolated nucleic acids molecules, designated B7-4 nucleic acid molecules, which encode novel B7-4 polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing B7-4 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a B7-4 gene has been introduced or disrupted. The invention still further provides isolated B7-4 proteins, fusion proteins, antigenic peptides and anti-B7-4 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: November 2, 2001Date of Patent: May 2, 2006Assignee: Dana-Faber Cancer Institute, Inc.Inventors: Gordon Freeman, Vassiliki Boussiotis, Tatyana Chernova, Nelly Malenkovich
-
Patent number: 5948758Abstract: The invention relates to therapeutic methods of using a substantially pure protein comprising the .beta.-subunit of a human glycoprotein involved in cellular adhesion, or a biologically active fragment thereof, or analog thereof. These therapeutic methods are useful for treating auto immune diseases and allograft rejection.Type: GrantFiled: March 4, 1997Date of Patent: September 7, 1999Assignee: Dana Faber Cancer Institute Inc.Inventors: Timothy Springer, Takashi K. Kishimoto, Thomas M. Roberts
-
Patent number: 5710262Abstract: HB15-related lymphocyte activation antigens, and nucleic acid sequences encoding HB15-related antigens are disclosed. Also disclosed are antibodies reactive with HB15.Type: GrantFiled: April 25, 1994Date of Patent: January 20, 1998Assignee: Dana-Faber Cancer Institute, Inc.Inventors: Thomas F. Tedder, Liang-Ji Zhou
-
Patent number: 5316920Abstract: Lymphocyte activation antigen HB15, and the human cDNA and gene sequences encoding HB15, are disclosed. HB15 is not expressed at detectable levels by circulating leukocytes but has a unique pattern of expression among tissues. HB15 is uniquely expressed by Langerhans cells within the skin and other subpopulations of dendritic cells. Also disclosed are antibodies reactive with HB15 and methods of using anti-HB15 antibodies, or other antagonists to HB15 function, to treat an immunological disorder, disease or syndrome.Type: GrantFiled: April 17, 1992Date of Patent: May 31, 1994Assignee: Dana-Faber Cancer Institute, Inc.Inventors: Thomas F. Tedder, Liang-Ji Zhou